TCH Chemotherapy Regimen for HER2-Positive Breast Cancer
TCH (docetaxel, carboplatin, trastuzumab) is a preferred anthracycline-free regimen for HER2-positive breast cancer, particularly valuable for patients at higher risk for cardiotoxicity, with standard dosing of docetaxel 75 mg/m² and carboplatin AUC 6 every 3 weeks for 6 cycles, plus trastuzumab continued for 1 year total. 1, 2
Standard Dosing and Administration
Three-Week Cycle Regimen (Preferred)
- Docetaxel: 75 mg/m² IV on day 1
- Carboplatin: AUC 6 IV on day 1
- Trastuzumab:
- Loading dose: 4 mg/kg IV on day 1
- Maintenance: 2 mg/kg IV weekly during chemotherapy
- After chemotherapy completion: 6 mg/kg IV every 3 weeks
- Cycle: Every 21 days for 6 cycles
- Total trastuzumab duration: 52 weeks (1 year) 3, 2
Weekly Alternative Regimen
- Paclitaxel: 80 mg/m² IV on days 1,8, and 15
- Carboplatin: AUC 2 IV on days 1,8, and 15
- Trastuzumab: 4 mg/kg loading, then 2 mg/kg weekly
- Cycle: Every 28 days 3
Clinical Context and Evidence
The BCIRG006 trial established TCH as a preferred regimen, demonstrating a disease-free survival hazard ratio of 0.67 (95% CI: 0.54-0.84, p=0.0006) compared to chemotherapy alone in 3,222 patients with HER2-positive, node-positive or high-risk node-negative breast cancer. 2 Critically, TCH showed less cardiotoxicity than anthracycline-containing regimens (AC followed by docetaxel plus trastuzumab), making it the preferred choice for patients with cardiac risk factors. 4
When to Use TCH
Preferred Indications:
- Adjuvant setting: HER2-positive, node-positive or high-risk node-negative disease 1
- Patients at higher cardiac risk: Those with pre-existing cardiac conditions, older age, or concerns about anthracycline cardiotoxicity 4
- Neoadjuvant setting: Stage II-III HER2-positive breast cancer, achieving pCR rates of 39-64% 5, 6, 7, 8
Important Caveat:
While retrospective evidence suggests anthracycline-based regimens may be superior in some HER2-positive tumors 1, the BCIRG006 trial showed no statistically significant difference in disease-free survival between TCH and anthracycline-containing regimens (AC-TH), making TCH an acceptable alternative, particularly when cardiac safety is prioritized. 2
Addition of Pertuzumab
Current guidelines now favor adding pertuzumab to TCH (creating TCHP regimen) for patients with T2 or N1 disease who have not received neoadjuvant pertuzumab. 1, 9 The pertuzumab dosing is:
- Loading: 840 mg IV day 1
- Maintenance: 420 mg IV every 21 days 3
Real-world evidence shows TCHP achieves pCR rates of 64% in neoadjuvant settings, though with increased toxicity requiring dose modifications in 65% of patients. 8
Toxicity Management
Common Adverse Events:
- Hematologic: Neutropenia (36% grade 3/4), anemia (89.9% any grade, 12% grade 3/4), thrombocytopenia (15% grade 3/4) 5, 10, 8
- Non-hematologic: Mucositis (85%), pain (83%), diarrhea (71%), anorexia (4% grade 3/4) 5, 8
- Cardiac: Asymptomatic LVEF decline >15% in 5.5-6.7% of patients; symptomatic heart failure is rare (0.5%) 9, 10
Key Management Points:
- Prophylactic loperamide reduces diarrhea frequency 11
- Dose reductions are common (22-65% of patients) but do not significantly impact pCR rates 12
- Dose intensity >85% shows no significant advantage over <85% for achieving pCR 12
- Cardiac monitoring is mandatory throughout trastuzumab therapy 1
Practical Considerations
Radiation therapy should be initiated after completion of chemotherapy, not concurrently. 1 For hormone receptor-positive disease, endocrine therapy should be given sequentially after chemotherapy completion. 1
The regimen is generally well-tolerated with manageable toxicities, though 34% of patients may experience treatment delays or discontinuation due to adverse events, primarily hematologic toxicity occurring in later cycles. 5 Despite this, completion rates remain high (96%), and the anthracycline-free approach provides an important cardiac-sparing option without compromising efficacy. 6